EUVIMEDEUVIMED entdecken
Crossref

From “cluster imitation” to “first generic”: the impact of market exclusivity incentives on Chinese generic drug manufacturers

Zhixue Liu, Xiaoqin Chen, Zonghua Wang, Yongfa Chen

Expert Review of Pharmacoeconomics & Outcomes Research · 09.08.2026 · 26 (7) · 973-985

DOI: 10.1080/14737167.2026.2715978 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 10.11.2026. Verfasst von Zhixue Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regulatory Affairs, Trinomab Biotechnology Co., Ltd., Zhuhai, China. Hauptthemen laut MEDLINE: Drugs, Generic, Drug Industry, Drug Development. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: China's generic drug industry has long suffered from 'clustering' and homogeneous competition, constraining structural upgrading. In 2021, the drug patent linkage system introduced a 12-month market exclusivity period for first-to-market generic drugs, representing a key institutional change aimed at incentivizing high-quality generic development. RESEARCH DESIGN AND METHODS: Using panel data from 1,248 firm-year observations of A-share listed pharmaceutical companies (2015-2023), this study employs a difference-in-differences model comparing chemical generic drug manufacturers (treatment group) with other pharmaceutical sub-sectors (control group) to estimate the net policy effect. RESULTS: The market exclusivity incentive significantly increased R&D intensity (by approximately 1.2% points, p < 0.01) and patent applications (by 18.5%, p < 0.05) in the treatment group. R&D human capital positively moderates the policy effect. Non-state-owned enterprises and firms in highly competitive sub-sectors exhibit stronger responsiveness. CONCLUSIONS: The market exclusivity period is positively associated with increased innovation inputs and outputs among Chinese generic drug manufacturers. However, given the short post-policy observation period and concurrent pharmaceutical reforms, these findings should be interpreted cautiously regarding broad causal claims about industry transformation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, GenericDrug IndustryDrug DevelopmentChinaHumansEconomic CompetitionPatents as TopicMotivationEast Asian People

Stichwörter der Autor:innen

China pharmaceutical industryGeneric drugdifference-in-differences (DID)first-to-file strategymarket exclusivitypatent linkage

Substanzen

Drugs, Generic

Autor:innen und Institutionen

  • Department of Regulatory Affairs, Trinomab Biotechnology Co., Ltd., Zhuhai, China.
  • Department of Quality, Nanjing Fumeiruixin TechnologyCo., Ltd., Nanjing, China.
  • Technical Director, Nanjing Fumeiruixin Technology Co., Ltd., Nanjing, China.
  • School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.

Zitieren

APA

Liu, Z., Chen, X., Wang, Z., & Chen, Y. (2026). From “cluster imitation” to “first generic”: the impact of market exclusivity incentives on Chinese generic drug manufacturers. Expert Review of Pharmacoeconomics & Outcomes Research, 26(7), 973-985. https://doi.org/10.1080/14737167.2026.2715978

Vancouver

Liu Z, Chen X, Wang Z, Chen Y. From “cluster imitation” to “first generic”: the impact of market exclusivity incentives on Chinese generic drug manufacturers. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(7):973-985. doi:10.1080/14737167.2026.2715978

BibTeX
@article{Liu2026,
  author = {Liu, Zhixue and Chen, Xiaoqin and Wang, Zonghua and Chen, Yongfa},
  title = {From “cluster imitation” to “first generic”: the impact of market exclusivity incentives on Chinese generic drug manufacturers},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  volume = {26},
  number = {7},
  pages = {973--985},
  doi = {10.1080/14737167.2026.2715978}
}
Kostenlos starten →